Eton develops and sells prescription treatments for rare diseases, mainly hormone and metabolic conditions. ETON reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for ETON are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
Each firm's latest rating on ETON in the past 90 days
Average 12-month target
Price targets for ETONThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plansSign in
Latest rating changes
Canaccord GenuityTarget raised
Aug 14Buy
B. Riley SecuritiesReiterated
Aug 14Buy
HC Wainwright & Co.Target raised
Aug 14Buy
HC Wainwright & Co.Maintained
Aug 11Buy
Craig-HallumMaintained
Jul 28Buy
Date
Firm
Action
Rating
Price target
Aug 14
Canaccord Genuity
Target raised
Buy
Aug 14
B. Riley Securities
Reiterated
Buy
Aug 14
HC Wainwright & Co.
Target raised
Buy
Aug 11
HC Wainwright & Co.
Maintained
Buy
Jul 28
Craig-Hallum
Maintained
Buy
Loading…
Whale Options Flow
90D
No whale options trades in ETON in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ETON is in one of them and how their past ETON trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Eton Pharmaceuticals
Eton develops and sells prescription treatments for rare diseases. Its products include hormone replacement therapies for adrenal insufficiency, a treatment for a childhood growth disorder, and products for metabolic conditions such as phenylketonuria, Wilson disease and tyrosinemia. The company is based in Deer Park, Illinois, and sells its products in the United States through its own sales force. Its products reach patients through specialty pharmacies, and its customers are mainly doctors who treat patients with these conditions.
